The Effects of 2′-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials

Nucleic Acid Therapeutics

Volumn 27, Issue 3, 2017, Pages 121-129

  Crooke, Stanley T ^a   Baker, Brenda F ^a   Witztum, Joseph L ^b   Kwoh, T Jesse ^a   Pham, Nguyen C ^a   Salgado, Nelson ^a   McEvoy, Bradley W ^a   Cheng, Wei ^a   Hughes, Steven G ^a   Bhanot, Sanjay ^a   Geary, Richard S ^a  

^a ISIS PHARMACEUTICALS   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Antisense; factor XI; Platelets; Safety; Thrombocytopenia

Indexed keywords

BLOOD CLOTTING FACTOR 11; MIPOMERSEN; PLACEBO; ANTISENSE OLIGONUCLEOTIDE; NUCLEOTIDE;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INDICATION; DRUG SAFETY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; OPEN STUDY; PARTIAL THROMBOPLASTIN TIME; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; ADULT; AGED; BLEEDING; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); COMBINATION DRUG THERAPY; DRUG EFFECTS; FEMALE; MALE; MIDDLE AGED; PLATELET COUNT; STATISTICS AND NUMERICAL DATA; THROMBOCYTOPENIA; TIME FACTOR;

ADULT; AGED; BLOOD PLATELETS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; FACTOR XI; FEMALE; HEMORRHAGE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; OLIGONUCLEOTIDES, ANTISENSE; PLATELET COUNT; THIONUCLEOTIDES; THROMBOCYTOPENIA; TIME FACTORS;

EID: 85020173493     PISSN: 21593337     EISSN: 21593345     Source Type: Journal    
DOI: 10.1089/nat.2016.0650     Document Type: Article

References (34)

1. Limmroth V, F Barkhof, N Desem, MP Diamond, G Tachas and ATL1102 Study Group. (2014). CD49d antisense drug ATL1102 reduces disease activity in patients with relapsingremitting MS. Neurology 83:1780-1788.
2. Crooke ST, BF Baker, TJ Kwoh, W Cheng, DJ Schulz, S Xia, N Salgado, HH Bui, CE Hart, et al. (2016). Integrated safety assessment of 2-O-methoxyethyl chimeric antisense oligonucleotides in non-human primates and healthy human volunteers. Mol Ther 24:1771-1782.
3. Laskin JJ, G Nicholas, C Lee, B Gitlitz, M Vincent, Y Cormier, J Stephenson, Y Ung, R Sanborn, et al. (2012). Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer. J Thorac Oncol 7: 579-586.
4. Saad F, S Hotte, S North, B Eigl, K Chi, P Czaykowski, L Wood, M Pollak, S Berry, et al.; Canadian Uro-Oncology Group. (2011). Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after firstline docetaxel: CUOG trial P-06c. Clin Cancer Res 17: 5765-5773.
5. Chi KN, SJ Hotte, EY Yu, D Tu, BJ Eigl, I Tannock, F Saad, S North, J Powers, ME Gleave and EA Eisenhauer. (2010). Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 28:4247-4254.
6. Chia S, S Dent, S Ellard, PM Ellis, T Vandenberg, K Gelmon, J Powers, W Walsh, L Seymour and EA Eisenhauer. (2009). Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer. Clin Cancer Res 15:708-713.
7. Natale R, F Blackhall, D Kowalski, R Ramlau, G Bepler, F Grossi, C Lerchenmüller, M Pinder-Schenck, J Mezger, et al. (2014). Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer: a randomized open-label phase II study. J Thorac Oncol 9:1704-1708.
8. Wiechno P, BG Somer, B Mellado, PL Ch?osta, JM Cervera Grau, D Castellano, C Reuter, M Stöckle, J Kamradt, et al. (2014). A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancer. Eur Urol 65:516-520.
9. Hong DS, R Kurzrock, Y Oh, J Wheler, A Naing, L Brail, S Callies, V Andre, SK Kadam, et al. (2011). A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res 17:6582-6591.
10. Glover JM, JM Leeds, TG Mant, D Amin, DL Kisner, JE Zuckerman, RS Geary, AA Levin, and WR Shanahan, Jr. (1997). Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302). J Pharmacol Exp Ther 282:1173-1180.
11. Henry SP, W Novotny, J Leeds, C Auletta and DJ Kornbrust. (1997). Inhibition of coagulation by a phosphorothioate oligonucleotide. Antisense Nucleic Acid Drug Dev 7:503-510.
12. Sheehan JP and HC Lan. (1998). Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex. Blood 92:1617-1625.
13. Sheehan JP and TM Phan. (2001). Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex by an allosteric mechanism. Biochemistry 40:4980-4989.
14. Kwoh TJ. (2007). An overview of the clinical safety experience of first-and second generation antisense oligonucleotides. In: Antisense Drug Technology Principles, Strategies, and Applications, 2nd edition. Crooke ST, ed. CRC Press, New York, pp. 365-399.
15. Henry SP, T Kim, K Kramer-Strickland, TA Zanardi, RA Fey and AA Levin. (2007). Toxicologic properties of 2-Omethoxyethyl chimeric antisense inhibitors in animals and man. In: Antisense Drug Technology Principles, Strategies, and Applications, 2nd edition. Crooke ST, ed. CRC Press, New York, pp. 327-363.
16. Sewell KL, RS Geary, BF Baker, JM Glover, TG Mant, RZ Yu, JA Tami and FA Dorr. (2002). Phase I trial of ISIS 104838, a 2-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. J Pharmacol Exp Ther 303:1334-1343.
17. Bü ller HR, C Bethune, S Bhanot, D Gailani, BP Monia, GE Raskob, A Segers, P Verhamme and JI Weitz. (2015). FXIASO TKA Investigators. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med 372:232-240.
18. Crosby JR, U Marzec, AS Revenko, C Zhao, D Gao, A Matafonov, D Gailani, AR MacLeod, EI Tucker, et al. (2013). Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates. Arterioscler Thromb Vasc Biol 33:1670-1678.
19. Younis HS, J Crosby, JI Huh, HS Lee, S Rime, B Monia and SP Henry. (2012). Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys. Blood 119:2401-2408.
20. Zhang H, EC Löwenberg, JR Crosby, AR MacLeod, C Zhao, D Gao, C Black, AS Revenko, JC Meijers, et al. (2010). Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood 116: 4684-4692.
21. Yu RZ, RS Geary, JD Flaim, GC Riley, DL Tribble, AA vanVliet and MK Wedel. (2009). Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2-Omethoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Clin Pharmacokinet 48:39-50.
22. Viney NJ, JC van Capelleveen, RS Geary, S Xia, JA Tami, RZ Yu, SM Marcovina, SG Hughes, MJ Graham, et al. (2016). Antisense oligonucleotides targeting apolipoprotein( a) in people with raised lipoprotein(a): two randomized, double-blind, placebo-controlled, dose-ranging trials. Lancet 388:2239-2253.
23. Finkel RS, CA Chiriboga, J Vajsar, JW Day, J Montes, DC De Vivo, M Yamashita, F Rigo, G Hung, et al. (2016). Nusinersen treatment of infantile-onset spinal muscular atrophy. Lancet 388:3017-3026.
24. Duell PB, RD Santos, B-A Kirwan, JL Witztum, S Tsimikas and JJP Kastelein. (2016). Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia. J Clin Lipidol 10:1011-1021.
25. Gaudet D, VJ Alexander, BF Baker, D Brisson, K Tremblay, W Singleton, RS Geary, SG Hughes, NJ Viney, et al. (2015). Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med 373:438-447.
26. Santos RD, PB Duell, C East, JR Guyton, PM Moriarty, W Chin and RS Mittleman. (2015). Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. Eur Heart J 36:566-575.
27. Tsimikas S, NJ Viney, SG Hughes, W Singleton, MJ Graham, BF Baker, JL Burkey, Q Yang, SM Marcovina, et al. (2015). Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet 386:1472-1483.
28. Gaudet D, D Brisson, K Tremblay, VJ Alexander, W Singleton, SG Hughes, RS Geary, BF Baker, MJ Graham, RM Crooke and JL Witztum. (2014). Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med 371: 2200-2206.
29. Raal FJ, RD Santos, DJ Blom, AD Marais, MJ Charng, WC Cromwell, RH Lachmann, D Gaudet, JL Tan, et al. (2010). Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 375:998-1006.
30. Crooke ST, ed. (2007). Antisense Drug Technology Principles, Strategies, and Applications, 2nd edition. CRC Press, New York.
31. Vickers TA and ST Crooke. (2016). Development of a quantitative BRET affinity assay for nucleic acid-protein interactions. PLoS One 11:e0161930.
32. Goemans NM, M Tulinius, M van den Hauwe, AK Kroksmark, G Buyse, RJ Wilson, JC van Deutekom, SJ de Kimpe, A Lourbakos and G Campion. (2016). Long-term efficacy, safety, and pharmacokinetics of drisapersen in Duchenne muscular dystrophy: results from an open-label extension study. PLoS One 11:e0161955.
33. FDA Briefing Document, NDA 206031. Drisapersen, Peripheral and Central Nervous System Drugs Advisory Committee Meeting (November 24, 2015), www. fda. gov/ downloads/advisorycommittees/committeesmeetingmaterials/ drugs/peripheralandcentralnervoussystemdrugsadvisory committee/ucm473737. pdf (accessed on September 22, 2016).
34. Bianchini D, A Omlin, C Pezaro, D Lorente, R Ferraldeschi, D Mukherji, M Crespo, I Figueiredo, S Miranda, et al. (2013). First-in-human phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castrationresistant prostate cancer. Br J Cancer 109:2579-2586.